FROM PRESS
to presentations

News

DECEMBER 7, 2021
PROMISING CLINICAL DATA ON REVALESIO'S RNS60 PRESENTED AT 32ND INTERNATIONAL SYMPOSIUM ON ALS/MND
FEBRUARY 23, 2021
REVALESIO SIGNS AGREEMENT TO DESIGN TRIAL WITH RNS60 FOR THE HEALEY ALS PLATFORM TRIAL
JANUARY 4, 2019
FDA GRANTS REVALESIO FAST TRACK STATUS FOR ALS INVESTIGATIONAL DRUG RNS60
All news

Publications

June 2020
RNS60 HAS THERAPEUTIC EFFECTS IN A MOUSE MODEL OF TRAUMATIC BRAIN INJURY (TBI)
March 2019
RNS60 TREATMENT WAS WELL TOLERATED IN AN OPEN LABEL CLINICAL PILOT STUDY IN ALS
June 2018
RNS60 INCREASES PRODUCTION OF NEW FUNCTIONAL MITOCHONDRIA IN NEURONAL CELLS
All Publications